Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cepheid announced it has received clearance from the Food and Drug Administration (FDA) to market Xpert Norovirus, an in vitro diagnostic test for identification and differentiation of Noroviruses genogroup I and II.
The Xpert Norovirus allows on-demand detection and differentiation between genogroups I and II, which contribute to the majority of human infections. Healthcare professionals can obtain accurate results within one hour.
RELATED: FDA Clears New Flu, RSV Dx Molecular Test
The Xpert Norovirus, as well as the recently approved Xpert Flu/RSV XC, run on the company’s GeneXpert system. The test will begin shipping this month.
For more information call (888) 838-3222 or visit Cepheid.com.
Related Content
